Abpro and China’s NJCTTQ Form $4-Billion Immuno-Oncology PartnershipBy
Abpro, a Woburn, Massachusetts-based biotechnology company developing antibody therapeutics, and NJCTTQ, a pharmaceutical company based in Nanjing, China, have entered into an agreement to develop multiple bispecific antibody therapies in immuno-oncology, including T-cell engagers. The collaboration leverages Abpro’s proprietary DiversImmune antibody discovery platform.
Under the terms of the agreement, Abpro is eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royalties. Abpro will retain all commercial rights for any approved molecules in geographies outside of China and Thailand while NJCTTQ will retain rights in China. Abpro and NJCTTQ will collaborate globally to pursue preclinical and clinical development and commercialization.
Abpro develops therapeutic candidates for immuno-oncology using two proprietary platforms: DiversImmune and Multimab. To date, the DiversImmune platform has generated antibodies against more than 300 unique targets. Abpro’s Multimab bispecific platform then enables the assembly of these antibodies into a variety of bi- and multi-specific antibody formats, tailored to each program. Abpro has used the DiversImmune and Multimab platforms to develop a pipeline of seven immuno-oncology therapeutic candidates, including T-cell engagers, as well as programs in ophthalmology and autoimmunity.